A study of a new weekly shot, tirzepatide, in people with heart failure with preserved ejection fraction.

Recruiting now. Registry record last updated October 31, 2025.

Who can join: Adults 18+, have heart failure with preserved ejection fraction.
What you take: tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 1.8 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor University of Texas Southwestern Medical CenterDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 120

What this study is for

Primary condition: HFpEF - Heart Failure With Preserved Ejection Fraction. Also studied in: Diabetic Cardiomyopathies.

Full scientific study title: Tailored Exercise Training Study Among Adults With HFpEF.

Who can join

Age18 and upSexAny

Adults 18+, have heart failure with preserved ejection fraction. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Age\>= 18 yrs
LVEF (Left Ventricular Ejection Fraction) \>= 50%
History of HFpEF or at risk of HFpEF
HFpEF diagnosis based on:- -HF hospitalization within 12 months-
NT-proBNP \>360 pg/mL

Key exclusion criteria

Hospitalization 1 month prior to baseline visit
History of recurrent falls
eGFR (Estimated Glomerular Filtration Rate) \<20ml/min/1.73m
Active changes in HF therapies over 2 weeks prior to baseline visit
Inability participate in exercise training therapy

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Texas1 site

University of Texas Southwestern Medical Center
Dallas, Texas
Ambarish Pandey, MD214-645-9868ambarish.pandey@utsouthwestern.edu

Follow this trial

We email you if NCT07223242 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: February 18, 2025. Expected completion: December 30, 2026. Last updated on ClinicalTrials.gov: October 31, 2025.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 28, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.